These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11284078)

  • 1. [Immunoglobulin treatment in dermatology].
    Volc-Platzer B
    Hautarzt; 2001 Mar; 52(3):264-77; quiz 277-9. PubMed ID: 11284078
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin therapy in dermatologic disorders.
    Cakmak SK; Gül U; Gönül M; Kiliç A; Soylu S
    Inflamm Allergy Drug Targets; 2008 Jun; 7(2):75-84. PubMed ID: 18691136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatology and Immunoglobulin Therapy: Who to Treat and How to Administer Immunoglobulins.
    Navarro-Triviño FJ; Pérez-López I; Ruíz-Villaverde R
    Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):323-330. PubMed ID: 29429551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases.
    Rütter A; Luger TA
    Curr Opin Investig Drugs; 2002 May; 3(5):713-9. PubMed ID: 12090544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatological uses of high-dose intravenous immunoglobulin.
    Jolles S; Hughes J; Whittaker S
    Arch Dermatol; 1998 Jan; 134(1):80-6. PubMed ID: 9449914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy in autoimmune disease--a review.
    Counihan TJ; Feighery C
    Ir J Med Sci; 1991 Jul; 160(7):199-205. PubMed ID: 1757213
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view.
    Ruetter A; Luger TA
    Am J Clin Dermatol; 2004; 5(3):153-60. PubMed ID: 15186194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study.
    Ruffatti A; Cerutti A; Favaro M; Del Ross T; Calligaro A; Hoxha A; Marson P; Leoni L; Milanesi O
    Clin Exp Rheumatol; 2016; 34(4):706-13. PubMed ID: 27385463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.
    Enk AH; Hadaschik EN; Eming R; Fierlbeck G; French LE; Girolomoni G; Hertl M; Jolles S; Karpati S; Steinbrink K; Stingl G; Volc-Platzer B; Zillikens D
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1657-1669. PubMed ID: 27406069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology].
    Hadaschik E; Eming R; French LE; Girolomoni G; Hertl M; Jolles S; Karpati S; Steinbrink K; Stingl G; Volc-Platzer B; Zillikens D; Enk A
    Hautarzt; 2020 Jul; 71(7):542-552. PubMed ID: 32435817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
    Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
    J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.
    Negi VS; Elluru S; Sibéril S; Graff-Dubois S; Mouthon L; Kazatchkine MD; Lacroix-Desmazes S; Bayry J; Kaveri SV
    J Clin Immunol; 2007 May; 27(3):233-45. PubMed ID: 17351760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyanosis of the foot.
    Shi VJ; Leventhal JS; Mensah KA; Galan A; Choate KA
    Cutis; 2017 Oct; 100(4):206;209;210. PubMed ID: 29136053
    [No Abstract]   [Full Text] [Related]  

  • 14. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).
    Smith DI; Swamy PM; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e1-54. PubMed ID: 17190617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravenous immunoglobulins in dermatology].
    Nydegger U; Hunziker T
    Ann Dermatol Venereol; 2002; 129(8-9):1078-81. PubMed ID: 12442118
    [No Abstract]   [Full Text] [Related]  

  • 16. If Roosevelt only knew.
    Jarin JD
    J Miss State Med Assoc; 2011 Mar; 52(3):76-8. PubMed ID: 21476465
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunomodulation of autoimmune and systemic inflammatory diseases with intravenous immunoglobulin.
    Mouthon L; Piketty C; Kazatchkine MD
    Vox Sang; 1994; 67 Suppl 3():53-9. PubMed ID: 7975512
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravenous immunoglobulin treatment of neurological autoimmune diseases.
    Stangel M; Hartung HP; Marx P; Gold R
    J Neurol Sci; 1998 Jan; 153(2):203-14. PubMed ID: 9511879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate.
    Ballester OF; Saba HI; Moscinski LC; Nelson R; Foulis P
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):106-8. PubMed ID: 1509289
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunoglobulins and corticoids in Guillain-Barre syndrome: a report of a new case. Letter].
    Riol Diego M; Jiménez Monteagudo M; López de Mesa R; Alzina de Aguilar V
    An Esp Pediatr; 1996 Nov; 45(5):547-9. PubMed ID: 9036793
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.